A Phase 1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Bemarituzumab in Combination with Other Anti-Cancer Therapies in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-103)
- Abdelrahim, Maen (PI)
- Bernicker, Eric H. (Key Personnel)
- Heyne, Kirk (Key Personnel)
- Singh, Monisha (Key Personnel)
- Zhang, Jun (Key Personnel)
Project: Clinical Trial